Evaluating the cost-effectiveness of voclosporin for the treatment of lupus nephritis in the United States. (PubMed, J Manag Care Spec Pharm) - May 8, 2024 - "The AURORA 1 study found that the use of voclosporin with low doses of mycophenolate mofetil and glucocorticoids yielded significant reductions in proteinuria. For a subpopulation of Black, Hispanic, and Latino patients, the incremental cost of voclosporin per QALY was $77,435 and per evLYG was $67,828. Following the inclusion of updated data in the cost-effectiveness analysis, voclosporin remains a cost-effective therapy for the treatment of active LN including in a Black, Hispanic, and Latino subpopulation, substantially below the ICER willingness-to-pay threshold of $150,000/QALY."
Cost effectiveness • HEOR • Journal • Chronic Kidney Disease • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus
|
|
Ernie Lee; Lisa Kennedy; Ronald Flauto; Vanessa Birardi; Victoria Atencio
|